Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 69   

Articles published

GSK 1,485.00 +6.50 (0.44%)
price chart
GSK clinches deal to buy Human Genome for $3 billion
LONDON/BOSTON (Reuters) - GlaxoSmithKline Plc is to acquire its long-time partner Human Genome Sciences Inc for a sweetened offer of about $3 billion (1.91 billion pounds), ending on friendly terms a three-month hostile pursuit of the U.S.
GlaxoSmithKline to acquire Human Genome Sciences  Baltimore Sun (blog)
GSK clinches $3B deal to buy Human Genome  National Post
Related articles »  
Glaxo in $3 Billion Settlement
Drug maker GlaxoSmithKline PLC agreed to plead guilty to criminal charges of illegally marketing drugs and withholding safety data from U.S.
GlaxoSmithKline to pay $3 billion in fines, the largest health care fraud ...  New York Daily News
Glaxo Pleads Guilty, Fined $1 Billion in Drug-Marketing Case  Businessweek
Related articles »  
GlaxoSmithKline fined $3 billion for off-label marketing
GlaxoSmithKline (GSK) has been fined $3 billion (�1.9 billion) for promoting two drugs for unapproved uses and failing to report safety data about a diabetes drug to the US Food and Drug Administration (FDA).
GlaxoSmithKline pays US$3-billion to settle biggest healthcare fraud case in ...  Financial Post (blog)
GlaxoSmithKline to pay $3 billion to settle US drug fraud scandal  Zee News
Related articles »  
Stocks That Avoid Unrecoverable Foreign Dividend Withholding In Tax Deferred ...
While we cannot be entirely certain, it appears that BHP (the Australian ADR for BHP Billiton plc) is partially franked. However, since the other BHP Billiton plc ADR (BBL) is U.K. based, paying a higher net yield (not subject to dividend tax ...
Hikma Beats GSK, Pfizer In Argatroban IP Infringement Row
Law360, New York (July 31, 2012, 7:17 PM ET) -- GlaxoSmithKline PLC and Pfizer Inc. on Tuesday failed to stop Hikma Pharmaceutical Co.
Q2 Earnings Report: GlaxoSmithKline, Eli Lilly and Bristol Myers Squibb
Three of the largest pharmaceutical companies have reported their earnings for the second quarter of 2012; GlaxoSmithKline plc (NYSE:GSK), Eli Lilly & Co. (NYSE:LLY), and Bristol Myers Squibb Co. (NYSE:BMY). GlaxoSmithKline plc (NYSE:GSK) reported ...
Earnings Preview: Bristol-Myers Squibb Company  Seeking Alpha
Related articles »  
Big Pharma is in big trouble � or should be
Something is definitely wrong in their management and monitoring systems. GSK are not able to say that the activities for which they were fined were anything other than deliberate.
Related articles »  
Glaxo Executives Cited in Case Now Lead Sanofi, Actelion
Two senior executives at GlaxoSmithKline Plc (GSK) singled out by the U.S. Justice Department for pushing the Advair asthma drug for unapproved uses have moved on to some of Europe's top pharmaceutical companies.
Related articles »  
Glaxo Tries to Shake Marketing Questions on Advair
According to the U.S. government, from 2001 through "at least 2010," Glaxo used illegal marketing tactics to promote Advair, an inhaler licensed to treat moderate to severe forms of asthma.
Related articles »  
SEC filing: GlaxoSmithKline makes clean sweep of Human Genome Sciences ...
Glaxo's Adrian Rawcliffe has been appointed Human Genome Sciences' chief financial officer, replacing David Southwell, and GSK General Counsel Daniel Troy has replaced James Davis as secretary of Human Genome. All but three of HGS' directors have ...
GlaxoSmithKline ejects executives from recently acquired Human Genome ...  Washington Post (blog)
Related articles »